Evidence map›Paper›PMID 38961986›Full record

ArticleHeliyon2024

Treatment coverage for depression in the general Spanish population and the impact of the Covid-19 pandemic.

Lea Francia, Riccardo De Giorgi, Elvira Lara, Blanca Dolz Del Castellar, Chiara Castelletti, Cristina Rodríguez-Prada, Joan Domènech-Abella, Beatriz Olaya, Josep Maria Haro, José Luis Ayuso Mateos

Erratum issuedAbstract read
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Lea FranciaInstituto de Investigación Sanitaria del Hospital Universitario de La Princesa, IIS Princesa, Spain.
Riccardo De GiorgiDepartment of Psychiatry, University of Oxford, Warneford Hospital, Warneford Lane, Oxford, X3 7JX, United Kingdom.
Elvira LaraInstituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Madrid, Spain.
Blanca Dolz Del CastellarInstituto de Investigación Sanitaria del Hospital Universitario de La Princesa, IIS Princesa, Spain.
Chiara CastellettiInstituto de Investigación Sanitaria del Hospital Universitario de La Princesa, IIS Princesa, Spain.
Cristina Rodríguez-PradaInstituto de Investigación Sanitaria del Hospital Universitario de La Princesa, IIS Princesa, Spain.
Joan Domènech-AbellaInstituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Madrid, Spain.
Beatriz OlayaInstituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Madrid, Spain.
Josep Maria HaroInstituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Madrid, Spain.
José Luis Ayuso MateosInstituto de Investigación Sanitaria del Hospital Universitario de La Princesa, IIS Princesa, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Despite the availability of effective antidepressant strategies, numerous people with depressive disorders remain untreated. The Covid-19 pandemic has affected healthcare services, especially the mental health sector. This study aims to explore the coverage of depression treatments in the general Spanish population and the impact of the Covid-19 pandemic. Methods: We used longitudinal data (2018 and 2022) from the general Spanish population: pre-pandemic n = 1512; mean age = 65.43 years ± 14.90; 56 % females; post-pandemic n = 909; mean age = 68.00 years ± 14.24; 54 % women. The International Classification of Disease 10th edition was used to diagnose lifetime depressive episodes and severity. We explored psychological and pharmacological treatment coverage via multiple logistic regressions adjusted for 4 covariates (sex assigned at birth, education level, age, Covid-19 pandemic) for participants with a diagnosis of depression. Results: Treatment coverage for depression in the pre-pandemic and post-pandemic samples was, respectively, 53.3 % and 51.9 %. We observed an association between severe depression and treatment coverage (OR = 2.77, 95%CI 1.05 to 7.75). We found no association between the COVID-19 pandemic and treatment coverage. Conclusions: The pharmacological treatment coverage was associated with severe types of depression. The prevalence rates of treatment coverage were similar in the pre- and post-COVID-19 pandemic attesting to the resilience of the mental health system in Spain.

Indexed as

AdultsAssessmentDepressive episodeNICE guidelines

Identifiers

PMID38961986
PMCPMC11219982

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.